Compare SCYX & NA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SCYX | NA |
|---|---|---|
| Founded | 1999 | 2019 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Semiconductors |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 60.4M | 58.5M |
| IPO Year | 2014 | 2021 |
| Metric | SCYX | NA |
|---|---|---|
| Price | $4.26 | $2.02 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $3.00 | N/A |
| AVG Volume (30 Days) | ★ 329.4K | 116.7K |
| Earning Date | 05-06-2026 | 03-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 61.36 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $257,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $608.78 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.57 | $1.58 |
| 52 Week High | $5.62 | $31.48 |
| Indicator | SCYX | NA |
|---|---|---|
| Relative Strength Index (RSI) | 72.96 | 41.66 |
| Support Level | $0.67 | $1.61 |
| Resistance Level | $5.62 | $2.98 |
| Average True Range (ATR) | 0.27 | 0.28 |
| MACD | 0.26 | -0.06 |
| Stochastic Oscillator | 73.19 | 16.36 |
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.
Nano Labs Ltd is a Web 3.0 infrastructure and product solution provider, as well as a crypto treasury company. It is focused on the development of HTC chips and HPC chips. In addition, the company has established BNB value investment and adopted BNB (a crypto token) as the primary reserve asset. Furthermore, it has launched the iPollo Claw, a dedicated hardware solution for the OpenClaw AI Agent Ecosystem. Nano Labs derives revenue mainly from its HTC and HPC offerings, which comprise Darkbird series HPC chips that feature high performance and high energy consumption efficiency, and Cuckoo series chips, used in GPUs. Geographically, the company generates maximum revenue from the People's Republic of China (PRC), and the rest from Singapore, Hong Kong, the United States, and other markets.